Marta G. R.
- Country
- Spain
- Department
- Medical Oncology
Research Overview
- Adjuvant Pembrolizumab and Paclitaxel Versus Surveillance in Early Triple-Negative Breast Cancer with High Stromal Tumor-Infiltrating Lymphocytes
- IZABRIGHT-Breast01: A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for Anti-PD1/PD-L1 Treatment
- PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT PLUS RIBOCICLIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+) BREAST CANCER (THE CADILLAC STUDY)
Data & Insights
Has run more than one trial at 18 of 123 partner sites.
Specializations
Breast Cancer and Precision Endocrine Oncology
Breast cancer is a central area of interest, with activity spanning hormone receptor-positive, HER2-negative, HER2-positive, and triple-negative breast cancer. The research landscape also includes advanced, metastatic, and early-stage breast cancer, with attention to biomarker-defined disease.
- ER-positive breast cancer
- HR+/HER2-negative disease
- HER2-positive breast cancer
- Triple-negative breast cancer
Therapeutic interests include endocrine therapy, CDK4/6 inhibition, PI3K-targeted treatment, and antibody-drug conjugates in molecularly selected breast cancer.
Thoracic and Gastrointestinal Solid Tumors
The investigator is involved in the treatment of non-small cell lung cancer, small cell lung cancer, head and neck squamous cell carcinoma, gastric cancer, gastroesophageal junction adenocarcinoma, and colorectal cancer, including advanced and metastatic settings.
- Non-small cell lung cancer
- Small cell lung cancer
- Head and neck squamous cell carcinoma
- Colorectal cancer
Therapeutic focus extends to targeted therapy, immunotherapy, and biomarker-driven approaches in EGFR-mutated, KRAS-altered, and HER2-expressing tumors.
Genitourinary and Gynecologic Malignancies
Clinical research includes prostate cancer, renal cell carcinoma, urothelial carcinoma, bladder cancer, ovarian cancer, and endometrial cancer, with activity across localized, recurrent, and metastatic disease.
- Metastatic castration-resistant prostate cancer
- Renal cell carcinoma
- Urothelial carcinoma
- Ovarian cancer
Therapeutic domains include androgen receptor-directed treatment, PARP inhibition, checkpoint blockade, and approaches for platinum-resistant gynecologic cancer.
Hematologic Malignancies and Cellular Therapies
The investigator is active in acute myeloid leukemia, multiple myeloma, diffuse large B-cell lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, and other B-cell malignancies.
- Acute myeloid leukemia
- Multiple myeloma
- Diffuse large B-cell lymphoma
- Chronic lymphocytic leukemia
Therapeutic interests include cell therapy, proteasome inhibition, immunomodulatory treatment, and antibody-based regimens for relapsed or refractory blood cancers.
Cardiometabolic, Liver, and Immune-Mediated Disease
Research activity also covers cardiovascular disease, heart failure, pulmonary hypertension, chronic liver disease, primary biliary cholangitis, chronic kidney disease, and autoimmune disease.
- Atherosclerotic cardiovascular disease
- Heart failure
- Primary biliary cholangitis
- Autoimmune disease
Therapeutic emphasis includes cardiometabolic risk reduction, anti-inflammatory treatment, hepatic disease management, and therapies for cholestatic pruritus and fibrotic disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.